This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Biomodels LLC, a preclinical research organization specializing in cancer support care, today announced that its customized research program allowed ActoGeniX NV, a development stage biopharmaceutical company, to rapidly attain Food and Drug Administration (FDA) approval for Phase 1b clinical trials of AGO13 in cancer patients with oral mucositis.
We care about your feedback. Let us know how we can improve your CancerCompass experience.